These include the number of metastatic LNs, the specific lymph node stations involved and their prognostic significance (i.e., stations no. 4d and 6) [64,65,66,67], patient comorbidities, nutritional status at diagnosis, tumor stage, grading, histologic variants, postoperative complications, lymphatic invasion, genetic predisposition, molecular expression (i.e., HER2 and PD-L1), mismatch repair/microsatellite instability (MMR/MSI), claudins, and the response to perioperative treatments [68,69,70,71,72]. Here, ERBB2 is linked to neoplasm.